Mike Lazur, Noesis vets form new agency, Lazur Hoyvald Goldstein Partners

Share this article:

Former Torre Lazur McCann Healthcare chief creative director Mike Lazur, and Commonhealth’s Noesis veterans Christian Hoyvald and Steven Goldstein joined forces to become managing partners of a new agency, Lazur Hoyvald Goldstein Partners.

The agency opened the doors to its offices this April in Bridgewater, NJ.

All three partners see brand-building as their principle goal and believe they have a “nice mixture” of backgrounds, the trio told MM&M during a recent phone interview.

Lazur started out as an art director and has been a creative director for most of his more than 30 years in the industry. Hoyvald spent 14 years on the client side, holding positions in senior brand management, finance and market research at Novartis, Bristol-Myers Squibb and Reliant Pharmaceuticals. Four years ago, he joined Noesis ultimately serving as its EVP, director of client services. Goldstein was SVP, creative director at Noesis and a member of the CommonHealth Management committee. He has worked on several award-winning campaigns throughout his 20-year career.

Of the four clients currently signed on with Lazur Hoyvald Goldstein, one is a large chain of diagnostic radiology centers, one is a manufacturer of globally marketed oral specimen collection and diagnostic devices, and another is a long-established manufacturer of prescription dermatological and surgical products.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.